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ABSTRACT 
 
One of the mechanism actions of antimalarial drugsis by an inhibiting on the enzyme dihydrofolate reductase 
(DHFR), an enzyme target antifolate drug. Epi-croomine and croomine, are alkaloids isolated from 
Stemonatuberosa showed DHFR inhibition with Ki  of 61.14 and 100.59 µM and KM values of30.68 and 27.06 µM at 
10 ppm. The IC50 to the DHFR of croomine and pyrimethamine were 5.29 and 7.71 µM, respectively. 
Tuberostemonine is not active to the enzyme. The kinetic analysis showed that both epi-croomine and croomine 
competitively inhibited to the human DHFR recombinant. The molecular modeling of the compounds to the human 
DHFR was estimate depi-croomine and croomine’s binding free energy of -6.66 and -7.60 kcal/mol. The docking 
showed that both epi-croomine and croomine could possibly form hydrogen bonds with the amino acid residue of 
theAla9, which residues on the active site of the enzyme. 
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INTRODUCTION 
 
Malaria, is major tropical disease, and public health problem. In 2012, WHO reported 104 countries being endemic 
of malaria.[1] In  Asia, India recorded the highest malarial infection cases (1,765,371) followed by Indonesia 
(347,197) and Myanmar (200,679).[2] In 2010, almost half of the total Indonesian population (234 million) lives at 
risk infection transmitted by Plasmodium falciparum[3] and the threat still remain now days.[4]High cases of malaria 
were recorded in the East part of Indonesia, such as M luku Islands, East of Nusa Tenggara, and West Papua 
contributed to more than 80% of the nation’s 450,00 confirmed malaria cases in 2011[5]. In 2013, WHO estimated 
that the number of deaths due to malaria in Indonesia is approximately 3,000 per year,[4]and new antimalarial drugs 
are necessary to explore here.  
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The first anti-malarial drug, quinine, is derived from Chincona bark, and was extensively used during the First 
World War. Growing upon resistance of quinine, chloroquine (CQ, quinine derivative) was synthesized an 
introduced in 1934.[6] Twenty years later, CQ resistant cases were reportd in South-East Asia. Artemisinine a new 
generation malarial drug is resistance also in South-East Asia, such as Thailand, Cambodia, Myanmar and 
Vietnam[1]. 
 
Pyrimethamine resistance was first recorded during theVietnam War in the1970’s. The drug remained in use apotent 
malarial medicine in Indonesia until 1990,[7] when resistance started was emergency. Resistance has also 
beenrecorded on combination therapy drugs sulfadoxin-pyrimethamine (SP) in Asia, Africa, and South of 
America[8]. Different antimalarial drug classes with different bearing mechanismof action have been identified 
including, pyrimethamine, asdihydrofolate reductase (DHFR) inhibitor. 
 
Resistance to pyrimethamine appeared as a result of spontaneous mutations of DHFR. The first mutation was at 108 
amino acid residue, and followed by mutations atamino acid residues at50, 59, 51, 164 resulting in decrease if 
binding of the pyrimethamine binding toDHFR[7,9,10]. Single codon mutation was reported in Africa (108 codon)[11], 
Vietnam (140)[12], Indonesia (50,59)[13], Bolivia (30, 50, 164)[12], Sudan (108, 59, 51)[14]; double mutation occurred 
in South-East of Asia (59/108) [11]; triple mutation was reported in China (51/59/108)[11], Oceania (59/108/164)[11], 
Peru (108/51/164)[9], Malawi (51/59/108)[15] andquadruple mutation was recorded in South of America 
(51/59/108/164)[11,16]. 
 
In Papua-Indonesia, SP is a second line antimalarial gent[17] and currently, has become ineffective, therefore the 
need anew class DHFR inhibitors is urgently required. In our easierresearch was able to isolate two prospective 
antimalarial alkaloids, epi-croomineand croominefrom the root extracts of Stemonatuberosa collected from Maluku, 
Indonesia[18].Pyrimethamineis an alkaloid synthesis with 2,4-pyrimidinediamine skeleton, whileepi-
croomine,crominesand tuberostemonineare alkaloids derived from a octahydro-pyrolo[1,2-a] azepine backbone[19]. 
In this paper we report the activity of epi-croomine, croomineand tuberostemonine as class of inhibitors of DHFR in 
vitro. Molecular docking studies were also performed to study the possible binding modes of these alkaloids to the 
DHFR active site. 
 
EXPERIMENTAL SECTION 
 
Human DHFR was purchased from Sigma. A 10 mMdihydrofolic acid stock solution (substrate) was prepared by the 
addition of 2.2 mL assay buffer pH 7.5 to 10 mg dihy rofolic acid. The stock solution 10 mM NADPH was made by 
the addition of 3 mL suspension buffer to 25 mg NADPH. Four inhibition studies on DHFR to thealkaloids 
(pyrimethamine, tuberostemonine, croomine and epi-croomine) were made as a 1000 ppm stock solution (in DMSO 
0.2% in suspension buffer). The final inhibitors soluti n concentrations were 0.1, 1, 10 and 100 ppm. The amount of 
DHFR in each reaction was 1.5 X 10–3 units. The volume of enzyme (5x dilutions) was 10 µL. The reactions were 
measured by the decrease in absorbance at λ 340 nm in an UV/Vis spectrophotometer. Alkaloids of croomine, epi-
croomine and tuberostemonine were isolated from the roots of S. tuberosa.[18] 
 
Table 1. The composition of reaction for DHFR assay 
 
No Compound DHFR (unit) 
NADPH 
(µL) 
DHFA 
(µL) 
Inhibitor 
(ppm) 
1 Blank 0.0015 9 - - 
2 Blank 0.0015 9 8 - 
3 Enzyme Activity 0.0015 9 8 - 
4 Pyrimethamine 0.0015 9 8 * 
5 Croomine 0.0015 9 8 * 
6 Epi-croomine 0.0015 9 8 * 
7 Tuberostemonine 0.0015 9 8 * 
Note: Assay buffer was 1500 µL/ sample; *) alkaloid conce trations were  0.1, 1.0, 10.0; 100.0 
 
The spectrophotometer was adjusted to 340 nm. In the reaction tube was add assay buffer to the test micro-
centrifuge tube according to the reaction (Table 1) and to the test being performed. Then, the DHFR enzyme or the 
sample to the appropriate tube was added, and homogenized. For activity assays, without testing an inhibitor, 
continue to transfer the content of the tube to be tested to a 1 mL quartz cuvette. Then, NADPH solutin and 
dihydrofolic acid were added. For inhibition assay only, add the inhibitor and mix well (pyrimethamine, 
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tuberostemonine, croomine and epi-croomine) at 0.1;1; 10 and 100 ppm concentration in the reaction. The 
absorbance at 340 nm decreases, due to a decrease in NADPH concentration.  
 
Ligand binding mode into human DHFR (hDHFR) was analyzed by docking molecular simulation using 
Autodock4[20]. Re-docking of native ligand (co-crystalization) was used for docking validation. The gridbox that 
generated complex structure more similar to native structure was used to dock the alkaloids in this paper. The three-
dimensional structure of hDHFRwas provided from theProtein Data Bank (PDB) with accession code 1HFP. The
gridbox docking was centered on 30.013, 17.759, -2.393 coordination, 19 x 19 x 19 size with spacing of 1.0 Å. 
Docking preparation was performed using program Autodock Tools 1.5.6 [21] and docking results were analyzed 
using PyMol 1.3 and Discovery Studio Visualizer 2.4. 
 
RESULTS AND DISCUSSION 
 
The activity of DHFR was recorded before incubating with the test compounds in which dihydrofolic acid 
(substrate) is converted to tetrahydrofolic acid through a reduction reaction. Three isolated alkaloids, epi-croomine, 
croomine, and tuberostemonine were incubated with DHFR and naturalsubstrate using pyrimethamine as the 
positive control. Percentage of the decrease of inhibition of DHFR was evaluated as a percent of reduction of DHFR 
activity (Table 1).  
 
The alkaloids showed no inhibitory activities at low  concentrations (0.1 and 1.0 ppm), while the pyrimethamine as a 
positive control showed 65% inhibition at 1.0 ppm.  At increasing concentration (10 ppm) epi-croomine and 
croomine started to show enzyme inhibition. At 100 ppm croomine showed almost complete inhibition (96.32%) of 
DHFR activity as well as pyrimethamine, but epicroomine is moderate and tuberostemonine is not active. The IC50 
to the DHFR was evaluated using Probit analyze of SPS  17.0 mode. The values IC50 to the DHFR of croomine 
andpyrimethamine were 5.29 and 7.71 µM, respectively.  
 
Table 1. The % inhibition activity of DHFR by alkaloids 
 
Compound 
The % inhibition activity of DHFR  
0.1 ppm 1 ppm 10 ppm 100 ppm 
Epi-croomine 0 0 21.17 25.88 
Croomine 0 0.88 36.32 96.32 
Tuberostemonine 0 0 15 15.58 
Pyrimethamine 2.20 65.28 70 100 
 
An enzyme interacts with anagonist in many ways forming an enzyme-substrate complex. The Kis were determined 
by calculations based on theKM values from DHFR with and without inhibitor of alkloids, from theexperimental 
data, via the Lineweaver-Burk plot using formula: 
 
 
 
 
 
Based on the Lineweaver-Burk graph, the Vmax and Km values (with and without inhibitors) are summarized in 
Table 2. 
 
Table 2. Kinetic constants for human DHFR activities to the epi-croomine and croomine 
 
Compounds Vmax 
(µM/ min) 
Km 
(µM) 
Ki 
(µM) 
No inhibitor 23.67 20. 66  
Epi-croomine  (10 ppm) 24.17 30.68 61.14 
Croomine  (10 ppm) 25.76 27.06 100.59 
 
TheLineweaver-Burk double reciprocal plot showed thatthe inhibited enzyme had similar Vmax valueswhile the 
presence of the inhibitor generated larger KM values. Vmaxof epi-croomine,croomine and without inhibitor are almost 
the sameof 24.17 ;25.76 and 23.67 µM, but KMvalues were different with inhibitor of 30.68 and 27.06 µM. From the 
percent of DHFR enzyme inhibition data in Table 1, the binding affinity (Ki) was evaluated for epi-croomine and 
max max
1 1 1
[ ]
mK
v V S V
  = +  
  
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croomine. The values Kiof epi-croomine
epi-croomineis bigger than croomine.
analysis of KM for a competitive inhibition reaction reflected an effective decrease in the enzyme affinity toward 
thesealkaloids due to theirinability to interact wih already inhibitor bounded enzyme.
affinities are derived from Ki=KM I/
for an inhibitor is analogous to Km for a substrate.
 
Table 3.Calculated
Ligand 
Furopyrimidine derivative
Tuberostemonine 
Epi-croomine 
Croomine 
Pyrimethamine 
 
Table 4. Visual of docking between alkaloids and DHFR 
 
Docking pose visualized
 
 
 
Alkaloids inhibition activity were evaluated by 
complex and to predict the relative binding free enrgies and to explore the possibility ofhydrogen 
these compounds and amino acid residues of DHFR wild
with code 1HFP (Tab. 3). 
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andcroomineare 61.14 dan 100.59µM, it indicated that 
 So, the inhibition of epi-croomine is also stronger than croomine.
For competitive inhibitors, the 
 KM(i) - KM while for non-competitive inhibitors, Ki=V
 
 values of binding free energy and H-bonding of alkaloids
 
Binding free energy (kcal/mol) H-bonding 
 -8.43 Ile7, Glu30, Asn64, Arg70, Val115
-8.06 Leu27 
-6.66 Ala9 
-7.60 Ala9 
-5.40 Ile7, Glu30, Val115, tyr121
enzyme 
 Protein-ligand interactions Ligand- amino acid interactions
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The estimation of binding free energy forepi-croomineand croominearealmost the sameof -6.66 and -7.60 kcal/mol 
(see Table 3) which indicated thatepi-cromine and croomine-enzyme complexesare more stable than 
pyrimethamine-enzyme complexof -5.40 kcal/mol.   
 
The docking studies (Tab. 4) indicated that epi-croomineand croominemight interact with Ala9 at the active site of 
DHFR through hydrogen bonding. Both epi-croomineand croomine interact with Ala9, but they have bind at 
differentpositions, epi-croomineand croomine bonded to oxygens of carbonyl at C-17 and C-12, respectively. 
 
CONCLUSION 
 
Konstanta inhibition (Ki) of epi-croomine is bigger than croomineat 10 ppm.  Both of epi-croomineand croomineare 
competitively inhibited to the human DHFR recombinant ndmight interact with Ala9 amino acid residue at the 
active site of DHFR through hydrogen bonding. 
 
Acknowledgments 
The authors thanks to Directorate General of Higher Education (DGHE), Ministry of National Education ad 
Cultures, Indonesia for funding this research through Bantuan Unggulan Perguruan Tinngi (BUPT) ofAirlangga 
University, Surabaya, Indonesia FY 2013.  
 
REFERENCES 
 
[1] WHO,  2012, World Malaria report 
[2] WHO, 2008, World Malaria report 
[3] Elyazar, I. R. F; Gething, P. W.; Patil, A. P.; Rogayah, H.; Kusriastuti, R.; Wismarini, D. M; Tarmizi, S. N; 
Baird, J. K.; Hay S. I. PLoS One.2011, 6, e37325. 
[4] Herdiana, H.; Fuad, A.; Asih, P.B. S.; Zubaedah, S.; Arisanti, R. R.; Syafruddin, D.; Kusnanto, H.; Sumiwi, M. 
E.;  Yuniarti, T.; Imran, A.; Rahmadyani, R.; Yani, M.; Kusriastuti, R.; Tarmizi, S. N.; Laihad, F. J.; Hawley, W. A. 
Malaria Journal. 2013,12, 2-13. 
[5] Kusriastuti, R.; Surya, A. Acta Med. Indones.-Indones. J. Intern. Med. 2012,44, 265-269. 
[6] Gregson, A.; Plowe, C. V. Pharmacol. Rev.2005, 57, 117–145.  
[7] Fitriah; Sulistyawati, S. S.; Riyanto, S.; Budiono; Basuki, S.; Dachlan, Y. P.; Uemura, H. The J of Tropical Life 
Sci.2012, 2, 92-98. 
[8] Gatton, L. M.; Martin, B. L.; Cheng, Q. Antimicrob. Agents Chemother.2004, 48, 2116–2123 
[9] Bacon, JD., Tang, D., Salas, C., Roncal, N., Lucas, C., Gerena, L., Tapia, L., Lianos-Cuentas, AA., Garcia, C., 
Solari, L., Kyle, D., Magili, AJ., Plos One 4(8):e6762, doi:10.1371/journal.phone.0006762 
[10] Delfino, R. T.; Santos-Filho, O. A.; Figueroa-Villar, J. D. Biophys. Chem.2002, 98, 287-300.  
11] Bloland Peter B., Drug resistance in Malaria, WHO/CDS/CSR/2001.4   
[12]Plowe, C. V.; Cortese, J. F.; Djimde, A.; Nwanywu, O. C.; Watkins, W. M.; Winstanley, P. A.; Estrada-
Franco, J. G.; Mollinedo, R. E.; Avila, J. C.; Cespdes, J. L.; Carter, D.; Doumbo, O. K. J. Infect. Dis.1997, 176, 
1590-1596. 
[13] Nagesha, HS, Din Syafrudin, Casay, GJ.,Susanti AI.,  
Fryauff DJ, Reeder JC, Cowman AF: Trans R Soc Trop Med Hyg,2001, 95:43-49 
[14] Yusuf, R. U.; Omar, S. A.; Ngure, R. M. J. Infect. Dev. Ctries. 2010, 4, 61-69. 
[15]Bwijo, B, Kaneko, A., Takechi, M., Zungu, IL., Moriyama, Y., Lum, JK., Tsukahara, T., Mita, T. Takashi, N., 
Bergqvist, Y., Bjorkman, A., Kobayakawa, T., ActaTropica, 2003, 85, 363-373 
[16] Kamchonwongpaisan, S.; Quarrell, R.; Charoensetakul, N.; Ponsinet, R.; Vilaivan, T.; Vanichtanankul, J.; 
Tarnchompoo, B.; Sirawaraporn, W.; Lowe, G.; Yuthavong, Y. J. Med. Chem. 2004, 47, 673-680. 
[17] Sorontou, Y.; Asih, P. B. S.; Wanandi, S. I.; Ramelan, W.; Syafruddin, D. Med. J. Indonesia, 2007, 16, 32-38. 
[18] Pudjiastuti, P.; Pyne, S. G.; Sugiyanto, Lie, W. PhytochemistryLett.2012, 5, 358–360. 
[19] Pyne, S. G.; Ung, A. T.; Jatisatienr, A.; Mungkornasawakul, P.  Int. J. Sci. Tech.2007, 1, 157-165. 
[20] Morris, G.M; Huey, R; Lindstrom, W; Sanner, M.F; Belew, R.K; Goodsell, D.S; Olson, A.J. J Comput Chem. 
2009, 30(16):2785-27891. 
[1] Sanner, M.F. J. Mol. Graphics Mod. 1999, 17:57-61. 
 
